Chimerix Inc (CMRX)

$3.55 -0.11 (-3.01%)
Market Cap 329.17M
Revenue (ttm) 320,000.00
Net Income (ttm) -82.10M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -25,656.25%
Debt to Equity Ratio 0.00
Volume 927,100
Avg Vol 5,252,716
Day's Range N/A - N/A
Shares Out 89.94M
Stochastic %K 63%
Beta 0.36
Analysts Strong Sell
Price Target $8.75

Latest News on CMRX

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

Dec 30, 2024, 7:00 AM EST - 18 days ago

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Dec 11, 2024, 2:19 PM EST - 5 weeks ago

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Dec 9, 2024, 4:01 PM EST - 5 weeks ago

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 6, 2024, 4:01 PM EST - 6 weeks ago

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 9:34 PM EST - 2 months ago

Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript

Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

Nov 1, 2024, 7:00 AM EDT - 2 months ago

Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 18, 2024, 4:31 PM EDT - 3 months ago

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Chimerix, Inc. (CMRX) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 11:50 AM EDT - 5 months ago

Chimerix, Inc. (CMRX) Q2 2024 Earnings Call Transcript

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

May 30, 2024, 7:00 AM EDT - 8 months ago

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript

May 1, 2024, 11:28 AM EDT - 9 months ago

Chimerix, Inc. (CMRX) Q1 2024 Earnings Call Transcript

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

May 1, 2024, 7:00 AM EDT - 9 months ago

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

Apr 24, 2024, 7:00 AM EDT - 9 months ago

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

Chimerix: Tackling A Strong Unmet Need With Promising Data

Mar 1, 2024, 3:31 PM EST - 11 months ago

Chimerix: Tackling A Strong Unmet Need With Promising Data

Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 1:42 PM EST - 11 months ago

Chimerix, Inc. (CMRX) Q4 2023 Earnings Call Transcript

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

Feb 29, 2024, 7:00 AM EST - 11 months ago

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

Feb 22, 2024, 7:00 AM EST - 11 months ago

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

Chimerix Appoints Lisa Decker to Board of Directors

Dec 29, 2023, 7:00 AM EST - 1 year ago

Chimerix Appoints Lisa Decker to Board of Directors

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Dec 4, 2023, 7:00 AM EST - 1 year ago

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Nov 16, 2023, 7:00 AM EST - 1 year ago

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

Oct 26, 2023, 7:00 AM EDT - 1 year ago

Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

Chimerix: Dangerous Road, Thesis Intact

Sep 8, 2023, 5:11 AM EDT - 1 year ago

Chimerix: Dangerous Road, Thesis Intact

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Aug 16, 2023, 10:05 AM EDT - 1 year ago

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Chimerix, Inc. (CMRX) Q2 2023 Earnings Call Transcript

Aug 5, 2023, 1:10 PM EDT - 1 year ago

Chimerix, Inc. (CMRX) Q2 2023 Earnings Call Transcript

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

Aug 3, 2023, 7:00 AM EDT - 1 year ago

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023

Jul 27, 2023, 7:00 AM EDT - 1 year ago

Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023

Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

Jun 27, 2023, 4:05 PM EDT - 1 year ago

Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

Chimerix: A High-Risk 'Lottery Ticket'

Jun 6, 2023, 4:50 PM EDT - 1 year ago

Chimerix: A High-Risk 'Lottery Ticket'

Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House

May 25, 2023, 7:00 AM EDT - 1 year ago

Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House

Chimerix, Inc. (CMRX) Q1 2023 Earnings Call Transcript

May 6, 2023, 5:41 PM EDT - 1 year ago

Chimerix, Inc. (CMRX) Q1 2023 Earnings Call Transcript

Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

May 4, 2023, 7:00 AM EDT - 1 year ago

Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023

Apr 27, 2023, 7:00 AM EDT - 1 year ago

Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023

Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting

Apr 18, 2023, 4:01 PM EDT - 1 year ago

Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting

Chimerix: Gaining Traction, Cash Runway To 2027

Mar 6, 2023, 9:00 AM EST - 2 years ago

Chimerix: Gaining Traction, Cash Runway To 2027

Chimerix, Inc. (CMRX) Q4 2022 Earnings Call Transcript

Mar 2, 2023, 10:36 AM EST - 2 years ago

Chimerix, Inc. (CMRX) Q4 2022 Earnings Call Transcript

Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

Mar 2, 2023, 7:00 AM EST - 2 years ago

Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

Jan 5, 2023, 7:00 AM EST - 2 years ago

Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update

Dec 8, 2022, 5:00 PM EST - 2 years ago

Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update

Chimerix Responds to Rubric Capital Management

Nov 10, 2022, 4:30 PM EST - 2 years ago

Chimerix Responds to Rubric Capital Management

Rubric Capital Management Sends Letter to Chimerix Board of Directors

Nov 10, 2022, 9:00 AM EST - 2 years ago

Rubric Capital Management Sends Letter to Chimerix Board of Directors

Chimerix, Inc. (CMRX) Q3 2022 Earnings Call Transcript

Nov 4, 2022, 10:19 PM EDT - 2 years ago

Chimerix, Inc. (CMRX) Q3 2022 Earnings Call Transcript

Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update

Nov 3, 2022, 7:00 AM EDT - 2 years ago

Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update

Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022

Oct 27, 2022, 4:30 PM EDT - 2 years ago

Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022

Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions

Sep 26, 2022, 4:05 PM EDT - 2 years ago

Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions

Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 7:00 AM EDT - 2 years ago

Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference

Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox

Aug 29, 2022, 10:45 AM EDT - 2 years ago

Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox

Chimerix: A Confusing Business Strategy Makes It Unconvincing

Aug 23, 2022, 6:28 PM EDT - 2 years ago

Chimerix: A Confusing Business Strategy Makes It Unconvincing

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Aug 23, 2022, 4:52 PM EDT - 2 years ago

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Chimerix, Inc's (CMRX) CEO Mike Sherman on Q2 2022 Results - Earnings Call Transcript

Aug 8, 2022, 11:16 PM EDT - 2 years ago

Chimerix, Inc's (CMRX) CEO Mike Sherman on Q2 2022 Results - Earnings Call Transcript

Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update

Aug 8, 2022, 4:01 PM EDT - 2 years ago

Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update